Dividend Assets Capital LLC Sells 13,093 Shares of LeMaitre Vascular, Inc. $LMAT

Dividend Assets Capital LLC lowered its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 18.1% in the first quarter, Holdings Channel.com reports. The institutional investor owned 59,093 shares of the medical instruments supplier’s stock after selling 13,093 shares during the quarter. LeMaitre Vascular makes up approximately 1.3% of Dividend Assets Capital LLC’s portfolio, making the stock its 29th largest holding. Dividend Assets Capital LLC’s holdings in LeMaitre Vascular were worth $6,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in LMAT. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares during the period. Geneos Wealth Management Inc. grew its holdings in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $47,000. Quarry LP raised its position in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 529 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 32.7% in the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 179 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on LMAT shares. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research reaffirmed an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of LeMaitre Vascular stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 54,453 shares of company stock worth $5,906,174. 7.40% of the stock is owned by corporate insiders.

LeMaitre Vascular Price Performance

LMAT stock opened at $102.88 on Monday. LeMaitre Vascular, Inc. has a twelve month low of $79.00 and a twelve month high of $118.01. The company has a market cap of $2.35 billion, a PE ratio of 37.96, a price-to-earnings-growth ratio of 2.86 and a beta of 0.52. The business’s 50-day simple moving average is $98.79 and its 200 day simple moving average is $97.29. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the prior year, the firm posted $0.48 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is presently 36.90%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.